Manganese superoxide dismutase (MnSOD) is a mitochondrial enzyme that defends against oxidative damage due to reactive oxygen species (ROS). A new isoform of MnSOD with cytotoxic activity was recently discovered in liposarcoma cells. Here, we tested the effectiveness of a recombinant form of this isoform (rMnSOD) on leukemic T cells, Jurkat cells, and lymphocytes. Our results confirm that leukemic T cells can internalize rMnSOD and that rMnSOD causes apoptosis of 99% of leukemic cells without showing toxic effects on healthy cells. Using light and electron microscopy, we determined that an rMnSOD concentration of 0.067 μM most effective on apoptosis induction. Western blot analysis showed that treatment with 0.067 μM rMnSOD resulted in high expression of the pro-apoptotic protein Bax and low expression of the anti-apoptotic protein Bcl-2 in leukemia cells. Concerning signal transduction pathway no influence was observed after treatment except for Jurkat cells showing a slightly decreased expression of ERK phosphorylation. These results suggest that rMnSOD may be an effective and non-toxic treatment option for T-cell leukemia.
various cancer types and the use of alternate pathways in response to oxidative stress.

A new isoform of MnSOD was recently discovered and isolated from the human liposarcoma cell line (LSA). LSA-type MnSOD differs from wild type human MnSOD by a single threonine to isoleucine substitution at amino acid 82, and its MW (around 30 kDa) is significantly higher than that of conventional MnSOD (24 kDa). Furthermore, unlike wild type MnSOD, which normally remains confined to the mitochondrial matrix (Hunter et al., 1997), LSA-type MnSOD is released from adipocytes into the medium (Mancini et al., 2006). As demonstrated by Mancini et al. (Mancini et al., 2008), recombinant LSA-type MnSOD (rMnSOD) has a distinctive capacity to penetrate and kill cancer cells expressing oestrogen receptors, without having cytotoxic effects on normal cells. The oncotoxic activity of rMnSOD is due to an increase in the level of oxidants both in tumor and leukemic cells, which contain low levels of catalase (Pica et al., 2010).

Recently mitochondrial alterations in cancer cells have been recognized as a target for cancer therapy (Barbosa et al., 2012). In spite of recent progress in therapy, approximately 25% of children and 50% to 70% of adults with T-ALL develop treatment resistant disease (Goldenberg et al., 2003), which carries a poor prognosis (Bassan et al., 2004). In this study we assess rMnSOD biological function to determine its oncotoxic effect on pediatric high-risk T-ALL and Jurkat cells and its influence on apoptosis and cellular proliferation mediated by the MAPK and AKT pathway.

### Materials and Methods

#### Reagents

The LSA-type MnSOD was isolated from human liposarcoma cell line (LSA) and obtained in recombinant form rMnSOD as reported by Mancini et al. (Mancini et al., 2006, 2008). rMnSOD was diluted in the medium of culture cells.

#### Culture cells

Lymphoblastic leukemia cells were collected from one patient diagnosed and treated for T-cell acute lymphoblastic leukemia (T-ALL) at the Pediatric Oncology Unit of Second University of Naples and purified by bone marrow using Ficoll Hystopaque density gradient centrifugation. Clinical characteristics of patient at diagnosis were: age 3 years old, white blood count 197000/mL, FAB classification L2, good prednisone responder and early T immunophenotype.

Leukemic lymphoblasts, Jurkat cells and lymphocytes from healthy donors (as control) were cultured at a density of $1 \times 10^6$ cells/mL in RPMI media supplemented with 1% Penstrep and 10% FBS in a humidified atmosphere containing 5% CO₂ at 37 °C.

#### Cell viability assay

Cell viability was analyzed by MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay. Cells were seeded in 96-well plates at the density of $1 \times 10^5$ cells/well in a final volume of 100 μL. Cells were then incubated at 37 °C in a humidified atmosphere to allow exponential growth. After 72 h of growth, cells were treated with rMnSOD at a final concentration ranging from 0.0067 μM to 0.67 μM, for 5 h. At 5 h from the treatment, cells were exposed to 10% MTT for 3 h at 37 °C to form a blue formazan precipitate, which was dissolved in dimethyl sulfoxide and measured.

### Table 1. Three-day-culture cell viability

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Cell concentration</th>
<th>Trypan blue (%)</th>
<th>Morphology</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-leukemic cells</td>
<td>T 0 1,000,000/mL</td>
<td>78%</td>
<td>NM. ND. Clump absent</td>
</tr>
<tr>
<td></td>
<td>T 1 400,000/mL</td>
<td>87%</td>
<td>NM. ND. Clump present</td>
</tr>
<tr>
<td></td>
<td>T 2 400,000/mL</td>
<td>65%</td>
<td>NM. ID. Clump present</td>
</tr>
<tr>
<td>Jurkat cells</td>
<td>T 0 1,200,000/mL</td>
<td>100%</td>
<td>NM. ND. Clump absent</td>
</tr>
<tr>
<td></td>
<td>T 1 800,000/mL</td>
<td>90%</td>
<td>NM. ID. Clump absent</td>
</tr>
<tr>
<td></td>
<td>T 2 800,000/mL</td>
<td>70%</td>
<td>NM. ID. Clump present</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>T 0 800,000/mL</td>
<td>100%</td>
<td>Normal morphology, normal density, increased density.</td>
</tr>
<tr>
<td></td>
<td>T 1 800,000/mL</td>
<td>90%</td>
<td>Normal morphology, normal density, increased density.</td>
</tr>
<tr>
<td></td>
<td>T 2 800,000/mL</td>
<td>70%</td>
<td>Normal morphology, normal density, increased density.</td>
</tr>
</tbody>
</table>

NM, normal morphology; ND, normal density; ID, increased density.
formazan crystals by reacting with metabolically active cells. The formazan crystals were solubilized in a 1 N isopropanol/HCl 10% solution at 37 °C for 30 min. The absorbance at 595 nm was then determined. Cell viability was determined by the formula: Cell viability of the treated wells—absorbance of the blank control wells)/(absorbance of the negative control wells—absorbance of the blank control wells) x 100%. Control cells (leukemic lymphoblasts, Jurkat cells and lymphocytes) were cultured under identical conditions but in the absence of rMnSOD. All experiments were performed in triplicate.

Cell cycle analysis
Jurkat cells were seeded at density of 1 x 10^6 and then incubated 24 h in humified atmosphere at 37 °C. The next day, the cells were treated with 0.067 μM rMnSOD for 5 h in humified atmosphere at 37 °C. After incubation, cells were washed in PBS 1×, pelleted, and stained with Propidium Iodide (PI) solution (50 mg PI in 0.1% Sodium citrate, 0.1% NP40, pH 7.4) for 30 min at 4 °C in the dark. Flow cytometry analysis was performed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA). To evaluate cell cycle, PI fluorescence was collected as FL2 (linear scale) by the ModFIT software (Becton Dickinson). The intracellular DNA content evaluation, was performed by analyzing 20000 events for each point in triplicate. Each experiment gave a S.D. less than 5%.

Evaluation of apoptosis by DNA-flow cytometry
Apoptotic cell death was analyzed by Annexin-V-FITC staining. Annexin-V-FITC binds to phosphatidylserine residues, which are translocated from the inner to the outer leaflet of the plasma membrane during the early stages of apoptosis. Apoptotic cell labeling was performed using an Annexin-V kit (MedSystems Diagnostics, Wien, Austria). Jurkat cells were seeded at the density 1 x 10^6 and then incubated 24 h in humidified atmosphere at 37 °C. Then the cells were treated with 0.067 μM rMnSOD and incubated at 37 °C for 5 h. After the incubation the cells were collected and centrifuged for 5 min at 1,500 rpm. Pellet was washed in PBS 1×, incubated with Annexin-V-FITC in a binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2) for 30 min at 4 °C. Analysis of apoptotic cells was performed by flow cytometry (FACScan, Becton Dickinson). 10 x 10^5 events were acquired for each sample. Analysis was carried out in triplicate.

Immunocytochemistry at light microscopy
Lymphoblastic leukemia cells, Jurkat cells, and lymphocytes were incubated for 5 h in the presence or absence of rMnSOD at a final concentrations ranging from 0.0067 to 0.67 μM. Subsequently, a cytoxin was used to smear cells onto slides. The smears were fixed in Zamboni solution (4% paraformaldehyde, 15% picric acid) for 60 min and then washed with 1× PBS and incubated for 5 min with 3% hydrogen peroxide to quench endogenous peroxidase activity. Immunostaining was performed using the DAKO LSA+a System HRP kit. Rabbit anti-rMnSOD-Lp (1:200), was incubated on slides for 30 min, followed by incubation with the biotinylated secondary antibody for 30 min and peroxidase-labeled streptavidin for 30 min. To complete the reaction, a substrate-chromogen solution was used. The smears were counterstained with hematoxylin.

Determination of the apoptotic index
Apoptotic cells and bodies were counted from several areas of each sample. The apoptotic index (AI) was estimated as the number of apoptotic cells and/or bodies per 1,000 tumor cells, expressed in percentages.

Immunogold method at transmission electron microscopy
Both leukemia cells and lymphocytes were incubated for 6 h in the presence or absence of rMnSOD at a final concentration ranging from 0.0067 to 0.67 μM. The cells were then fixed using 0.1% glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium cacodylate buffer for 60 min at room temperature and washed twice in 0.1 M sodium cacodylate buffer. Samples were then fixed with 1% OsO4 for 10 min, dehydrated, embedded in Epon 812, and polymerized at 60 °C for 24 h. Ultrathin sections were prepared using a Leica Ultracut UCT ultramicrotome and mounted on nickel grids. The sections were subsequently subjected to antigen unmasking in citrate buffer, incubated with 10% hydrogen peroxide for 10 min, washed 3 times in PBS 0.9% for 5 min, and incubated in BSA 1% and glycine 0.15% in PBS for 30 min. The samples were incubated with polyclonal rabbit anti-rMnSOD-Lp (1:20) in Tris-HCl 0.05 mol/L with 1% BSA overnight at 4 °C.

TABLE 2. Cell cycle analysis

<table>
<thead>
<tr>
<th></th>
<th>UL necrosis</th>
<th>UR late apoptosis</th>
<th>LL living cells</th>
<th>LR early apoptosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTR 10^6 events</td>
<td>3.8</td>
<td>5</td>
<td>90.8</td>
<td>0.4</td>
</tr>
<tr>
<td>rMnSOD 0.067 μM 10^6 events</td>
<td>2.5</td>
<td>23.7</td>
<td>67.1</td>
<td>6.6</td>
</tr>
</tbody>
</table>

UL, upper left (necrosis); UR, upper right (late apoptosis); LL, lower left (viable); LR, lower right (early apoptosis); CTR, Untreated cells. Insets, % of positive cells.
washed three times in PBS 0.9% for 10 min, and incubated with a donkey anti-rabbit secondary antibody conjugated to 15 nm colloidal gold diluted (1:10) in 0.1% BSA for 2 h at room temperature. The sections were washed in PBS (pH 7.4) and distilled water prior to counterstaining with uranyl acetate and lead citrate. Ultrathin sections were examined using a LEO 912AB Zeiss transmission electron microscope.

**Protein extraction and western blot analysis**

Protein extraction was performed on ice for 30 min using lysis-buffer (1 M Tris-HCl pH 8, 5 M NaCl, 0.5 M NaF, 100% NP40) with protease-inhibitors (4 µL/mL PMSF, 2 µL/mL aprotinin and pepstatin, 1 µL/mL Na Ortovanadate). Cell lysates were centrifuged at 20,000 g for 2 min at 4 °C, and proteins were extracted from supernatant. Total protein concentration was determined using Bradford assay (Bio-Rad). For Western blot analysis, 30 µg of total protein was run on 10% polyacrylamide gel and blotted onto PVDF membrane (Millipore, Marlborough, MA). The membrane was blocked in 5% nonfat dry milk dissolved in TBS buffer (2 mM Tris, 13.7 mM NaCl, 0.1% tween-20, pH 7.6) overnight. All washes were performed in TBS buffer.

Immunoblotting was performed using primary antibodies against Bcl-2 (100), Bax (N20), AKT (H-136), pAKT (Ser473), ERK (G-12), and pERK (E-4) (Santacruz Biotechnology, INC) (1:500) incubated for 1 hour. Secondary antibodies (Santacruz Biotechnology 1:5000) were incubated at room temperature for 1 hour. Bands were visualized using a chemiluminescent system (ECL-Amersham). The intensity of each band was acquired with a CCD camera and analyzed with Quantity One 1-D analysis software (Biorad Laboratories). Results were normalized against the level of α-actin expression in each sample.

**Detection of reactive oxygen species**

Cell samples were pretreated with or without 10 mM NAC (Sigma—Aldrich, Saint Louis) at 37 °C for 20 min, and incubated with 0.067 µM rMnSOD for 5 h, then the cells were washed with PBS 1 ×
and incubated with 10 μM 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA-Cayman, Baerno, Italy) at 37 °C for 20 min. DCFH-DA diffused into cells is deacetylated by cellular esterases to non-fluorescent 2’,7’-Dichlorodihydrofluorescin (DCFH), which is rapidly oxidized to highly fluorescent 2’,7’-Dichlorodihydrofluorescein (DCF) by ROS. The fluorescence intensity is proportional to ROS levels within the cell cytosol; the fluorescence intensity was assessed using a Hitachi (Model U-2000) double-beam spectrophotometer with excitation at 484 nm and emission at 530 nm. Background fluorescence (conversion of DCFH-DA in absence of homogenate) was corrected by the inclusion of parallel blanks.

**Results**

**Effects of rMnSOD on growth inhibition on human T-ALL cells, Jurkat cells and lymphocytes**

Cells were cultured and monitored for 3 days to assess cellular concentration and proliferation using Trypan blue exclusion assay and MTT tests (Table 1).

To perform the experiments with the optimal dose of rMnSOD, we initially determined the dose-dependent survival rate of Jurkat and T-ALL upon rMnSOD treatment. We observed, based on Trypan blue exclusion assay and MTT tests, a less than 5% cell death after 5 h treatment with 0.003 μM rMnSOD, whereas a significant reduction in cell viability (by ~30%, data not shown) was induced by a 5 h treatment with 0.067 μM rMnSOD. Thus, 0.067 μM rMnSOD was selected for the subsequent experiments to minimize the apoptosis-induced alteration in protein expression.

In details, after 72 h of growth, cells were treated with 0.067 μM rMnSOD for 5 h in culture. We observed, with MTT test, a proliferation rate of 1% T-ALL cells, 40% Jurkat and 70% lymphocytes (Fig. 1A). Moreover with Trypan blue exclusion assay, performed in the same conditions, we observed a growth inhibition of 99% T-ALL cells, 60% Jurkat and 30% lymphocytes (Fig. 1B). Spontaneous proliferation curves of Jurkat cells line, T-ALL and lymphocytes were used as normalized controls. These curves showed an increase of Jurkat cell’s growth, a decrease of lymphocyte growth after 48 h and a slight decrease followed by a stabilization of T-cell ALL’s growth after 48 h to 96 h (Fig. 1C).

![Fig. 5. Apoptotic index percentages of apoptotic Jurkat cells following rMnSOD treatments.](image)

**Fig. 5.** Apoptotic index percentages of apoptotic Jurkat cells following rMnSOD treatments.

![Fig. 6. Jurkat cells by TEM following immunoreaction with anti-rMnSOD revealed by 15 nm colloidal gold particles: A-B) cell treated with 0.0067 μM rMnSOD showing an initial pre-apoptotic nuclear incision and slight cytoplasmic fragmentation; C) and D) cell treated with 0.067 μM rMnSOD which lead to a clear nuclear and cytoplasmic apoptotic fragmentations; E-F) cell treated with 0.67 μM rMnSOD, that shows membrane rupture. Lymphocytes treated with increasing concentrations of rMnSOD respectively followed by immunorevealing with anti-rMnSOD and 15 nm colloidal gold particles. G) and H) Control cells; I) and J) lymphocytes treated with 0.067 μM rMnSOD displaying a well-being condition while in K) and L) lymphocytes treated with 0.67 μM rMnSOD show cell damage.](image)

**Fig. 6.** Jurkat cells by TEM following immunoreaction with anti-rMnSOD revealed by 15 nm colloidal gold particles: A-B) cell treated with 0.0067 μM rMnSOD showing an initial pre-apoptotic nuclear incision and slight cytoplasmic fragmentation; C) and D) cell treated with 0.067 μM rMnSOD which lead to a clear nuclear and cytoplasmic apoptotic fragmentations; E-F) cell treated with 0.67 μM rMnSOD, that shows membrane rupture. Lymphocytes treated with increasing concentrations of rMnSOD respectively followed by immunorevealing with anti-rMnSOD and 15 nm colloidal gold particles. G) and H) Control cells; I) and J) lymphocytes treated with 0.067 μM rMnSOD displaying a well-being condition while in K) and L) lymphocytes treated with 0.67 μM rMnSOD show cell damage.
Effect of rMnSOD on apoptosis induction

After the treatment with 0.067 μM rMnSOD, we evaluated the induction of apoptosis on Jurkat cells by FACS analysis, after staining with Annexin-V-FITC and PI, as above described. As shown in Figure 2 and Table 2, a significant increase of apoptotic cells compared to control cells has been detected. In details, we found that the treatments with 0.067 μM rMnSOD for 5 h induced apoptosis in 23.7% of Jurkat cells, compared to 5% untreated cells.

Light microscopy

The treatments performed respectively with 0.0067, 0.067 and 0.67 μM rMnSOD for 5 h on the three cell populations gave the following percentages of labeled cells: 40%, 60% and 76% of cultured leukemic T cells; 60%, 73% and 100% of Jurkat cells and 60%, 70% and 75% of lymphocytes, while the controls displayed no labeling (Fig. 3A). Overall, these results indicate that most cells internalized rMnSOD, as they displayed both mainly cytoplasmic and less nuclear immunoreactivity (Fig. 4 A–F, H–J). The percentages of viability as a result of the three concentrations of rMnSOD tested are reported in Figure 3B.

Leukemic T-cell and Jurkat cells

The T leukemic cells and Jurkat cells, treated with 0.67 μM rMnSOD, displayed cytoplasmic and nuclear positivity as well as rupture of the plasma membrane, (Figs. 4 F, 6E–F). In contrast, both the cells treated with 0.0067 and 0.067 μM rMnSOD showed cytoplasmic positivity as well as the pre-apoptotic changes of early and complete nuclear and cytoplasmic fragmentation (Figs. 4 A–E, 6A–D).
The plasma membrane (Figs. 4J, 6K) showed cytoplasmic and slight nuclear positivity as well as rupture of the plasma envelope (Figs. 6A–F, I–L), confirming that rMnSOD enters the cells. The internalization of rMnSOD was also evident in nuclear and cytoplasmic apoptotic fragments (Figs. 6C–D) and in damaged cells (Figs. 6E–F). rMnSOD also enters lymphocytes, as indicated by the presence of the 10 nm-gold particles distributed in the cytoplasm (Figs. 6I–L) after the 5 h treatment. No labeling was observed in untreated cells (Figs. 6G–H).

**Detection of reactive oxygen species**

N-acetylcysteine (NAC) resulted in blocking of rMnSOD-induced ROS generation, as shown in Figure 8. In fact 10 mM NAC induced a DCF decrease, following incubation with 0.067 μM rMnSOD, while the treatment without NAC, showed fluorescence comparable to the control. These data suggest that 0.067 μM rMnSOD induces ROS production in much higher amounts than in controls, as expected.

**Discussion and Conclusions**

It is well known that leukemic cells produce high levels of reactive oxygen species and have a disturbance of the protective role of enzyme against free radical. This variability of cell antioxidant machinery and ROS production, according to the cancer type, may be explained by the level of antioxidant defense which lead to a ROS production effective in generating neoplastic cell transformation but not enough to trigger apoptosis. Increasing evidence demonstrates the key role of ROS in the regulation of cell life and death. The toxic potential of ROS is able to activate the immune response. Thus, the development of new therapeutic interventions must deal with the duality of ROS in both protective cytotoxic against "non self" action and injurious action of their exceeding accumulation able to induce carcinogenesis (Manda et al., 2009). Similarly the rMnSOD shows a duality of action too, being able to trigger apoptotic death of cancer cells while oxygenates the healthy cells, or, if it exceeds the ability of catalase to transform the peroxide into oxygen and water, can induce necrosis in both tumor cells and healthy cells (Mancini et al., 2006). So the redox balance appears to be the main mechanism of carcinogenesis control (Manda et al., 2009 Barbosa et al., 2012). The rMnSOD used in the present study, was previously demonstrated to exert oncosuppressive activity in vitro and in vivo on tumor cells expressing oestrogen receptors (Mancini et al., 2006). The effect of internalized rMnSOD was hypothesized to be the increase of oxidant levels which are known to mediate cell killing (Mashiba and Matsunaga, 1998; Mainous et al., 2005).

In this study, we demonstrated that rMnSOD treatment induce apoptosis in both cultured ALL patient cells and in Jurkat cells treated with 0.67 μM rMnSOD showed cytoplasmic and slight nuclear positivity as well as rupture of the plasma membrane (Figs. 4J, 6K); whereas cells treated with 0.0067 or 0.067 μM rMnSOD showed no morphological alterations (Figs. 4H–J, 6I–L). Lymphocytes (not treated with rMnSOD) displayed no positivity (Figs. 4G, 6G). These findings indicate that 0.0067 and 0.067 μM rMnSOD cause apoptosis of only leukemic cells, instead 0.67 μM rMnSOD is a toxic concentration.

**Determination of the apoptotic index**

The number of the cells displaying both apoptotic nuclear and cytoplasmic fragmentation is reported in Figure 5.

**Transmission electron microscopy**

We used transmission electron microscopy (TEM) to confirm the internalization of rMnSOD by leukemic T cells, Jurkat cells, and lymphocytes treated with 0.0067, 0.067 and 0.67 μM rMnSOD. Our TEM results show colloidal gold particles (10 nm) dispersed mainly in the cytoplasm and sometimes near the mitochondrial envelope (Figs. 6A–F, I–L), confirming that rMnSOD enters the cells. The internalization of rMnSOD was also evident in nuclear and cytoplasmic apoptotic fragments (Figs. 6C–D) and in damaged cells (Figs. 6E–F). rMnSOD also enters lymphocytes, as indicated by the presence of the 10 nm-gold particles distributed in the cytoplasm (Figs. 6I–L) after the 5 h treatment. No labeling was observed in untreated cells (Figs. 6G–H).
cell line, without adverse effects on lymphocytes. In fact we showed that 0.067 μM rMnSOD causes apoptosis of leukemic T cells and of Jurkat cells in vitro and we observed (by MTT assay) a survival rate of 1% T-ALL cells, 40% Jurkat and 70% lymphocytes after treatment with rMnSOD. Moreover, we showed that 0.067 μM rMnSOD up regulates the pro-apoptotic protein Bax and inhibits the anti-apoptotic protein Bcl-2 in leukemic T cells. This data are in accordance with Mancini et al. (Mancini et al., 2006) on breast cancer cells who confirm a strong up regulation of pro-apoptotic Bax gene expression in the presence of rMnSOD, suggesting that this treatment might induce the apoptotic cascade. The possible involvement of an apoptotic mechanism was suggested by the strong inhibition of anti-apoptotic Bcl-2 gene expression detected in tumor cells in the presence of rMnSOD (Mancini et al., 2008). In addition, FACS analysis of cells treated with 0.067 μM rMnSOD displayed an evident increase of apoptotic cells in 23.7% of Jurkat cells, as compared to control cells.

Interestingly, leukemic cells internalize the exogenous rMnSOD that converts free radicals present in H₂O₂. Notably, catalase detoxifies H₂O₂ into molecular oxygen and it is usually in lower amount in leukemic cells than in healthy cells. (Battisti et al., 2008). Thus, treatment with rMnSOD may lead to accumulation of H₂O₂ and subsequent death of leukemic cells. In contrast, lymphocytes do not show this reduction in catalase activity and can tolerate high levels of endogenous H₂O₂ production. However, a concentration of 0.67 μM rMnSOD is toxic to leukemic cells and to lymphocytes; in fact at this concentration the rMnSOD induces necrosis due to a stochiometric imbalance that is created between the enzymes MnSOD and catalase. In conclusion, our findings suggest that rMnSOD could be considered as an associated additional treatment for leukemia, particularly as low concentrations of rMnSOD seem specifically toxic to cancer cells while having a protective effect on healthy cells. According to the current knowledge about the therapeutic target role of the redox balance (Manda et al., 2009; Barbosa et al., 2012), these results suggest an action for the rMnSOD which would achieve a good therapeutic efficiency and no side effects.

Acknowledgments

This work was partially supported by AIL (Italian Association against Leukemia-Lymphoma and Myeloma Division “Valentino Picazio” and partially by AGOP (Parent Association Pediatric Oncology). TEM observations have been performed at Zoological Station of Naples Anton Dohrn: the authors are grateful to Franco Iamurro for his technical assistance. The authors are grateful to the “Lega Italiana Per La Lotta Contro I Tumori di Napoli” for their partial financial support.

Literature Cited


